Stéphanie Pépin

633 total citations
23 papers, 507 citations indexed

About

Stéphanie Pépin is a scholar working on Epidemiology, Molecular Biology and Immunology. According to data from OpenAlex, Stéphanie Pépin has authored 23 papers receiving a total of 507 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Epidemiology, 7 papers in Molecular Biology and 7 papers in Immunology. Recurrent topics in Stéphanie Pépin's work include Influenza Virus Research Studies (22 papers), Respiratory viral infections research (15 papers) and Immune Response and Inflammation (6 papers). Stéphanie Pépin is often cited by papers focused on Influenza Virus Research Studies (22 papers), Respiratory viral infections research (15 papers) and Immune Response and Inflammation (6 papers). Stéphanie Pépin collaborates with scholars based in France, United States and Finland. Stéphanie Pépin's co-authors include Camille Salamand, Mélanie Saville, Yves Donazzolo, Alen Jambrecina, Martin Dupuy, Sandrine Samson, Jean‐Michel Scherrmann, Charles Lutsch, Martine Denis and Nolwenn Nougarede and has published in prestigious journals such as PLoS ONE, The Lancet Infectious Diseases and Pharmaceutical Research.

In The Last Decade

Stéphanie Pépin

22 papers receiving 492 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stéphanie Pépin France 15 423 163 141 69 67 23 507
Marina Stukova Russia 13 329 0.8× 266 1.6× 173 1.2× 115 1.7× 34 0.5× 66 534
Jose Capellan Canada 4 474 1.1× 170 1.0× 152 1.1× 59 0.9× 71 1.1× 5 540
Iris A. de Bruijn Netherlands 10 420 1.0× 106 0.7× 199 1.4× 66 1.0× 54 0.8× 12 512
Geert Leroux–Roels Belgium 9 412 1.0× 110 0.7× 139 1.0× 68 1.0× 36 0.5× 16 504
Teresa Aydillo United States 12 386 0.9× 284 1.7× 127 0.9× 56 0.8× 31 0.5× 26 584
Helen Dillon United Kingdom 4 412 1.0× 158 1.0× 123 0.9× 41 0.6× 84 1.3× 4 460
Louise Carolan Australia 13 612 1.4× 242 1.5× 230 1.6× 75 1.1× 28 0.4× 27 767
Samuel Wilks United Kingdom 7 232 0.5× 155 1.0× 113 0.8× 77 1.1× 14 0.2× 12 381
Han-hua Fang China 7 403 1.0× 148 0.9× 117 0.8× 51 0.7× 40 0.6× 18 448
Diane J. Post United States 4 304 0.7× 109 0.7× 128 0.9× 75 1.1× 27 0.4× 8 351

Countries citing papers authored by Stéphanie Pépin

Since Specialization
Citations

This map shows the geographic impact of Stéphanie Pépin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stéphanie Pépin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stéphanie Pépin more than expected).

Fields of papers citing papers by Stéphanie Pépin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stéphanie Pépin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stéphanie Pépin. The network helps show where Stéphanie Pépin may publish in the future.

Co-authorship network of co-authors of Stéphanie Pépin

This figure shows the co-authorship network connecting the top 25 collaborators of Stéphanie Pépin. A scholar is included among the top collaborators of Stéphanie Pépin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stéphanie Pépin. Stéphanie Pépin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Folegatti, Pedro M., Stéphanie Pépin, Katherine Fries, et al.. (2025). Comparative assessment of immunogenicity and safety of recombinant influenza vaccine in children, adolescents, and adults: results from a phase 3, immunobridging, open-label, non-randomised study. The Lancet Infectious Diseases. 25(10). 1097–1105. 2 indexed citations
2.
Palmu, Arto A., Stéphanie Pépin, Ritva Syrjänen, et al.. (2024). High‐Dose Quadrivalent Influenza Vaccine for Prevention of Cardiovascular and Respiratory Hospitalizations in Older Adults. Influenza and Other Respiratory Viruses. 18(4). e13270–e13270. 5 indexed citations
3.
Palmu, Arto A., Sangita Kulathinal, Kari Auranen, et al.. (2024). Development of Real-Time Surveillance for Serious Adverse Events in a Pragmatic Clinical Trial Using National Registers in Finland. Clinical Epidemiology. Volume 16. 901–915.
4.
Pépin, Stéphanie, Jean‐François Nicolas, Henryk Szymański, et al.. (2021). Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial. Human Vaccines & Immunotherapeutics. 17(12). 5475–5486. 25 indexed citations
5.
6.
Guerche‐Séblain, Clotilde El, Annick Moureau, Camille Schiffler, et al.. (2019). Epidemiology and burden of influenza in healthy children aged 6 to 35 months: analysis of data from the placebo arm of a phase III efficacy trial. BMC Infectious Diseases. 19(1). 308–308. 15 indexed citations
7.
8.
Arredondo-Garcı́a, José Luis, Martin Dupuy, Céline Petit, et al.. (2019). Immunogenicity and safety of a multi-dose quadrivalent inactivated influenza vaccine in individuals aged 6 months to 17 years: a randomized phase III trial. Human Vaccines & Immunotherapeutics. 16(6). 1380–1384. 3 indexed citations
9.
10.
Lazarus, Rajeka, Sarah Kelly, Matthew D. Snape, et al.. (2016). Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults. PLoS ONE. 11(11). e0165384–e0165384. 3 indexed citations
11.
Nolan, Terry, Charissa Borja-Tabora, Ferdinandus J. de Looze, et al.. (2015). Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial. Vaccine. 33(21). 2485–2492. 43 indexed citations
12.
Pépin, Stéphanie, Yves Donazzolo, Alen Jambrecina, Camille Salamand, & Mélanie Saville. (2013). Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults. Vaccine. 31(47). 5572–5578. 77 indexed citations
13.
Vesikari, Timo, Stéphanie Pépin, Inca Kusters, Agnès Hoffenbach, & Martine Denis. (2012). Assessment of squalene adjuvanted and non-adjuvanted vaccines against pandemic H1N1 influenza in children 6 months to 17 years of age. Human Vaccines & Immunotherapeutics. 8(9). 1283–1292. 24 indexed citations
14.
Vliet, Diane van der, Stéphanie Pépin, Michel Lambert, et al.. (2010). Similar immunogenicity of the A/H1N1 2009 pandemic influenza strain when used as a monovalent or a trivalent vaccine. Human Vaccines. 6(10). 823–828. 15 indexed citations
15.
Garcia, Jean‐Michel, Stéphanie Pépin, Nadège Lagarde, et al.. (2009). Heterosubtype Neutralizing Responses to Influenza A (H5N1) Viruses Are Mediated by Antibodies to Virus Haemagglutinin. PLoS ONE. 4(11). e7918–e7918. 36 indexed citations
16.
Leroux‐Roels, Isabel, Marie Van der Wielen, Corinne Vandermeulen, et al.. (2009). Humoral and cellular immune responses to split-virion H5N1 influenza vaccine in young and elderly adults. Vaccine. 27(49). 6918–6925. 20 indexed citations
17.
Chotpitayasunondh, Tawee, Usa Thisyakorn, Chitsanu Pancharoen, Stéphanie Pépin, & Nolwenn Nougarede. (2008). Safety, Humoral and Cell Mediated Immune Responses to Two Formulations of an Inactivated, Split-Virion Influenza A/H5N1 Vaccine in Children. PLoS ONE. 3(12). e4028–e4028. 30 indexed citations
18.
Höschler, Katja, Robin Gopal, Nick Andrews, et al.. (2007). Cross‐neutralisation of antibodies elicited by an inactivated split‐virion influenza A/Vietnam/1194/2004 (H5N1) vaccine in healthy adults against H5N1 clade 2 strains. Influenza and Other Respiratory Viruses. 1(5-6). 199–206. 14 indexed citations
19.
Salamand, Camille, et al.. (2005). Long-term clinical trial safety experience with the inactivated split influenza vaccine, Vaxigrip®. Vaccine. 24(10). 1586–1592. 30 indexed citations
20.
Pépin, Stéphanie, et al.. (1995). Snake F(ab′)2 Antivenom from Hyperimmunized Horse: Pharmacokinetics Following Intravenous and Intramuscular Administrations in Rabbits. Pharmaceutical Research. 12(10). 1470–1473. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Marina Stukova Breakdown of academic impact, for papers by Jose Capellan Breakdown of academic impact, for papers by Iris A. de Bruijn Breakdown of academic impact, for papers by Geert Leroux–Roels Breakdown of academic impact, for papers by Teresa Aydillo Breakdown of academic impact, for papers by Helen Dillon Breakdown of academic impact, for papers by Louise Carolan Breakdown of academic impact, for papers by Samuel Wilks Breakdown of academic impact, for papers by Han-hua Fang Breakdown of academic impact, for papers by Diane J. Post
Rankless by CCL
2026